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Intractable ascites associated with
mycophenolate in a simultaneous kidney-
pancreas transplant patient: a case report
Nina T. Weber1†, Ali Sigaroudi2†, Alexander Ritter1, Andreas Boss3, Kuno Lehmann4, David Goodman5,
Stefan Farese6, Stefan Weiler2 and Thomas F. Mueller1*
Abstract
Background: Mycophenolic acid (MPA), either given as an ester pro-drug or as an enteric-coated sodium salt, is
the most commonly prescribed anti-proliferative immunosuppressive agent used following organ transplantation
and widely applied in immune-mediated diseases. Clinicians are well aware of common adverse reactions related to
MPA treatment, in particular diarrhea, leukopenia and infections. Here we report a case of severe, persistent ascites
associated with MPA treatment. The otherwise unexplained and intractable ascites, requiring repeated paracenteses
for more than 8 months, rapidly ceased with stopping the MPA treatment. To our knowledge this is the first case of
severe ascites associated with MPA treatment reported in the scientific literature.
Case Presentation: A 45-year old female with type 1 diabetes mellitus received a simultaneous kidney-pancreas
transplant. The surgery was uneventful. However, post-operatively she developed severe transudative ascites requiring in
total more than 40 paracenteses treatments draining in the average 2.8 l of ascites fluid. The ascites formation persisted
despite exclusion of a surgical complication, fully functioning kidney and pancreas allografts, lack of any significant
proteinuria, normalization of circulating albumin levels, intensive use of diuretics and deliberate attempts to increase the
intervals between the paracentesis treatments. Various differential diagnoses, including infectious, hepatic, vascular and
cardiac causes were ruled out. Nine months after surgery enteric-coated mycophenolate sodium was switched to
azathioprine after which ascites completely resolved. When mycophenolate was recommenced abdominal fullness and
weight gain reoccurred. The patient had to be switched to long-term azathioprine treatment. More than 1 year post-
conversion the patient remains free of ascites.
Conclusion: MPA is the most widely used antimetabolite immunosuppressive agent. We suggest to consider MPA
treatment in the differential diagnosis of severe and unexplained ascites in transplant and non-transplant patients.
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Background
Mycophenolic acid (MPA) is the key anti-proliferative
immunosuppressant used in organ transplant recipients.
MPA is available as an ester pro-drug mycophenolate mo-
fetil (MMF, CellCept®, Roche Pharma, Reinach, CH) or as
an enteric-coated sodium salt mycophenolate sodium
(EC-MPS, Myfortic®, Novartis Pharma, Rotkreuz, CH).
MPA is a reversible inhibitor of inosine monophosphate
dehydrogenase (IMPDH). The anti-proliferative effect on
lymphocytes is the predominant mechanism by which
MPA exerts its immunosuppressive effects [1, 2]. The
major adverse effects associated with MPA include gastro-
intestinal, hematological and infectious complications,
with diarrhea and leukopenia being clinically the two most
relevant [3, 4]. In this report we describe a case of severe,
refractory transudative ascites occurring in a female
kidney-pancreas transplant recipient associated with
EC-MPS treatment. Ascites resolved after medication dis-
continuation and likely recurred with medication re-
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challenge. To our knowledge this the first case describing
severe ascites in association with mycophenolate therapy.
Case Presentation
Patient information
A 45-year old Caucasian female (weight 53 kg, BMI
19.6 kg/m2) with longstanding type 1 diabetes mellitus
received a simultaneous kidney-pancreas transplant. The
patient had no known drug allergies. She neither smoked
nor had a history of heavy alcohol consumption. Prior to
transplantation the patient had been on peritoneal dialy-
sis for 5 months without complications. The Tenckhoff
catheter was removed during transplantation surgery.
The initial immunosuppressive regimen consisted of
anti-thymocyte globulin, steroids, tacrolimus with a
target 12-h trough level of 10–15 μg/L, and EC-MPS
720 mg twice daily. There were no peri- or post-
operative surgical complications. Dual graft function was
immediate and excellent with normalization of estimated
glomerular filtration rate to 55–65 ml/min per 1.73m2
within 3 days and good glycemic control without
exogenous insulin use. Within 2 weeks after transplant-
ation, however, the patient complained of anorexia, nau-
sea and abdominal fullness. Dyspnea was denied.
Physical exam, diagnostic assessment and timeline
Physical examination revealed shifting dullness consist-
ent with ascites and mild peripheral edema. Abdominal
ultrasound confirmed the presence of ascites with nor-
mal hepatic parenchyma. There was no portal vein
thrombosis and normal hepatopetal portal venous flow.
The wedged hepatic venous pressure was 12 mmHg
compared to a central venous pressure of 6 mmHg,
effectively ruling out portal hypertension or veno-
occlusive disease with a pressure gradient of 6 mmHg.
Furthermore there were no esophageal or gastric varices
seen on upper gastrointestinal endoscopy. Liver stiffness
measured by ultrasound-based transient elastography
was 6.4 kPa (normal <7 kPa) making fibrosis or cirrhosis
very unlikely. Based on the normal findings of flow,
morphology, pressures and stiffness a liver biopsy was
not performed.
CT scanning of the abdomen was performed that
excluded anastomotic leakage from the renal artery and
vein or from the duodenal anastomosis to the proximal
jejunum. However it confirmed extensive ascites forma-
tion in all four abdominal quadrants (Fig. 1). Chest
x-rays revealed no signs of pleural effusion. Cardiac
ultrasound demonstrated a normal sized left ventricle
with a normal ejection fraction of ≥55%. There was mild
diastolic dysfunction without features of pulmonary
hypertension, right ventricular function and dimensions
were normal.
Diagnostic and therapeutic paracentesis was performed
for the first time 18 days after transplantation and re-
peated multiple times over the following 8.5 months
(Fig. 2). In total more than 40 times ascites fluid was
drained first with an indwelling catheter, later by fluid
taps, on average 2.8 l each time. The peritoneal fluid was
always clear. The cellular counts were low (< 100 cells/μl)
with normal distribution and no pathologic cells. Multiple
cultures and Gram stains were negative for pathogens.
Analysis of ascitic fluid showed a total protein content
between 8 and 23 g/L and albumin content between 5 and
17 g/L. The ascitic fluid showed consistently a high
serum-to-ascites albumin gradient (SAAG, average of
23 g/l, range between 17 and 28 g/l), indicating portal
hypertension.
Repeated measurements of both pancreatic amylase and
creatinine in the ascitic fluid were performed to rule out
leakage from the pancreatic or ureteric anastomosis, re-
spectively. The amylase concentration was mildly increased
on one occasion (ascites amylase 92 U/L, serum amylase
155 U/L, ratio of 0.59). Laboratory tests including INR
Fig. 1. CT-scan in the parenchymal phase after iv-injection of iodinated
contrast agent on day 18 after combined kidney-pancreas transplantation.
Small bowel is filled with oral contrast-agent, colon structures with rectal
contrast agent. The kidney transplant (KT) in the left lower abdomen still
exhibits a ureteral stent. In the upper part of the pancreas transplant (PT)
the anastomosis to the small bowel is visible. Both, kidney and pancreas
grafts display normal contrast agent uptake behavior. Extensive ascites (As)
can be seen in the four quadrants of the abdomen, moreover anasarca
(An) is shown in the subcutaneous tissue of both flanks
Weber et al. BMC Nephrology  (2017) 18:360 Page 2 of 6
(international normalized ratio), platelet count, thyroid and
liver function tests (ALT and bilirubin) were within the
normal ranges. The complete blood counts were normal
except for a slight leukopenia attributed to the immunosup-
pressive therapy. C-reactive protein (CRP) was elevated in
the first two post-operative months and normalized later
on. Initial urine protein levels were between 1.0 and 1.8 g
per day (in spot urine) which quickly resolved to 0.1 to
0.35 g per day over the period of observation. Serological
testing for hepatitis A, B and C as well as HIV was negative.
MPA 12-h through levels were 1.8 and 3.9 mg/L in two dif-
ferent analyses (using CEDIA® Mycophenolic Acid Assay,
Fisher Scientific Inc., Reinach, CH). There is no validated
target range but these results do not suggest overdosing.
Differential diagnosis
After ruling out technical complications, persistent edema
and ascites were explained by a combination of early post-
operative factors associated with simultaneous kidney-
pancreas transplant surgery in a small-sized patient, such as
high volume state, low oncotic pressures, activation of the
inflammation cascade and previous peritoneal dialysis treat-
ment. However, despite significant volume loss, increasing
serum protein levels, full clinical recovery, and periods of
deliberate withholding paracentesis despite abdominal
distension and distress to prevent a fluid circle of removal
and refilling, the ascites formation and need paracentesis
persisted. The high SAAG levels suggested portal
hypertension-related ascites but both hepatic and cardio-
genic causes were extremely unlikely given the normal find-
ings on imaging and pressure measurements. Infectious or
malignant causes were ruled out as far as possible. Given
the fact that the patient performed peritoneal dialysis with
high transporter status only for a short period of time pre-
transplant makes peritoneal sclerosis as contributing factors
to ascites formation extremely unlikely [5]. The literature
suggests nephrogenic ascites in the setting of kidney trans-
plantation mainly in association with rejection and
unrecognized heart dysfunction, neither of which was
present in our case [6, 7]. One report from 2012 discusses a
very rare case of nephrogenic ascites due to an exophytic
spongiform lesion on the surface of the renal allograft caus-
ing massive transudate ascites formation [8]. The patient
was treated by cauterization of the majority of the surface
of the allograft, which lead to an involution of the lesions
and finally resolution of ascites formation.
All those potential causative factors, as discussed in a
recent review of post-transplant ascites [6], were seen as
unlikely explanations for the persistence and severity of
ascites in our patient.
Interventions
Paracentesis was necessary every 1–4 weeks for several
months tapping up to 8 l of fluid each time. A trial with
diuretic treatment with spironolactone did not achieve a
sustained effect. In addition deliberately trying to pro-
long the intervals between paracenteses treatments were
not tolerable due to significant weight gain and discom-
fort for the patient. Overall the patient became progres-
sively more distressed with abdominal distension and
the need for repeated paracentesis. Based on the Swiss
drug information registry indicating an association of
40
45
50
55
60
65
70
0 90 182 274 366 456 547 639 731
b
o
d
y 
w
ei
g
h
t 
in
 k
g
postoperative day
period of repeated ascites drainages
EC-MPS
AZA AZA
TAC
CSA
EC-MPS
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tacrolimus with the development of ascites and pleural
effusions the immunosuppressive regimen was changed
6 months after transplantation by substituting cyclospor-
ine A for tacrolimus. This did not reduce the ascites or
the need for paracentesis. Further literature review noted
the association of EC-MPS with abdominal tension in
<1/100 to >1/1000 cases (Swiss product information).
Therefore, despite the increased immunological risk and
potential serious consequences, EC-MPS was switched to
azathioprine 8.5 months after transplantation (see Fig. 2).
This conversion was associated with a rapid resolution of
the ascites. Seven days after EC-MPS was stopped the last
paracentesis was performed. While on azathioprine the
patient became progressively neutropenic despite reducing
the daily dose and normal thiopurine methyltransferase
enzyme activity. Finally azathioprine was discontinued
after 1.5 months of therapy and EC-MPS 360 mg twice
daily was recommenced. This was associated with the im-
mediate sensation of abdominal tension and weight gain.
Withdrawal of EC-MPS again led to rapid improvement
of the symptoms. No other medications were changed
during this time period implicating re-exposure to EC-
MPS as the likely cause of ascites.
Follow-up and outcome
This case report suggests a rare adverse reaction of MPA
treatment. Our patient developed severe, refractory asci-
tes shortly after transplantation. Despite multiple investi-
gations we could not explain the development and
persistence of this intractable ascites extending through-
out all four abdominal quadrants. There were no surgi-
cal complications, no visible peritoneal or intestinal
abnormalities, no abdominal infection, no portal hyper-
tension, and no evidence of impaired hepatic or cardiac
function. Switching tacrolimus to cyclosporine did not
reduce the ascites. However, the conversion from EC-
MPS to azathioprine was associated with the resolution
of the ascites. The re-exposure to EC-MPS 6 weeks later
immediately caused abdominal tension and weight gain.
Therefore, a clear temporal relationship between EC-
MPS administration and ascites formation, with cessa-
tion of ascites following drug withdrawal and rapid
recurrence following re-challenge, was seen. Now, with a
follow up of more than 2 years the patient remains free
of ascites, her transplant functions are stable, 2 non-
complement binding donor-specific antibodies are un-
changed and the most recent kidney transplant biopsy
shows no significant pathology.
An adverse drug reaction was considered highly prob-
able, categorized as medically important and reported to
regulatory authorities. Based on the WHO/CIOMS
(World Health Organisation/Council for International
Organizations of Medical Sciences) causality scale in
Pharmacovigilance the causality between ascites
formation and EC-MPS was categorized as “certain”
(temporal relationship, positive de- and re-challenge,
exclusion of other differential diagnoses).
Discussion and conclusions
The diagnosis of MPA-induced ascites was based on the
results of investigations which excluded alternative
causes, the timing of onset and resolution of ascites after
discontinuation of therapy and finally the recurrence of
symptoms and signs with re-challenge with EC-MPS.
Taken together these observations strongly support
causality to the suspected adverse drug reaction [9].
MPA, as main constituent of EC-MPS and MMF, defines
the largely similar side-effect profile of both drugs [4]. A
search in VigiBase, the World Health Organization
global database of Individual Case Safety Reports identi-
fied from a total of 19,338 reports involving MPA 90
cases of ascites between the years 2000 and 2015. In 88
cases MPA was reported as a suspected drug. In 4 cases
“ascites” was the only reported side-effect and in just 2
patients MPA was reported as the only suspected drug.
Causality assessment or de- and re-challenge were not
reported in the WHO database. To our knowledge there
are no cases of severe ascites associated with MPA treat-
ment reported in the scientific literature.
In the presented case we describe MPA-associated
ascites formation with positive de-challenge after exclu-
sion of various differential diagnoses. Upon re-challenge
with MPA although the patient’s symptoms were highly
suggestive of repeated ascites formation we were unable
to obtain confirmation of ascites formation prior to drug
cessation which was done elsewhere. The impact of
MPA re-challenge is therefore not objectively proven,
however the rapid resolution of ascites upon initial ces-
sation of MPA strongly supports a causative association.
The pathomechanism of the MPA-associated ascites for-
mation in our patients is not clear. Gastrointestinal ad-
verse effects are a common complication of MPA
treatment [4]. Known MPA-associated morphological
gastrointestinal toxicity includes duodenal villous atro-
phy in renal transplant recipients [10], mucosal damage
of the stomach and erosive or ulcerative enterocolitis
[11]. Genetic polymorphisms of MPA metabolism and
transport might account for individual differences in side
effects. However, clinically severe ascites formation has
not been published as a complication of MPA treatment.
An increase in capillary permeability was considered as
explanation. In rats treated with MMF elevated levels of
nitric oxide were detected in the serum as well as in the
duodenum. Histopathologic examinations showed villous
atrophy and inflammatory cell infiltration. Gastrointes-
tinal disorders among these animals were therefore
attributed to local inflammatory reactions which were
possibly caused by elevated NO and myeloperoxidase
Weber et al. BMC Nephrology  (2017) 18:360 Page 4 of 6
levels [12]. However MPA is better known for its inhibi-
tory effects on inflammation [1, 4]. In a mouse model of
pleurisy, MMF suppressed protein levels of inflammatory
cytokines such as TNFα, IL1β, VEGFα and IL-17 [4, 13].
In a model of encapsulating peritoneal sclerosis MMF
reduced inflammation and neovascularization by inhibit-
ing VEGF and TGFβ1 [14]. Hence, this inhibition of
vascular growth factors and inflammatory cytokines
would rather lead to a decrease of vascularity, tightening
of the blood-peritoneal-barrier, less vasodilatation, re-
duced capillary leakage and therefore less ascites forma-
tion. An inflammation-induced increase in capillary
permeability is also not compatible with the high SAAG
gradient, low protein content and lack of inflammatory
cells in the transudative ascitic fluid in our patient.
In summary MPA treatment should be added to the
differential diagnosis of severe ascites. Given the world-
wide use of MPA as antimetabolite of choice in
immunosuppressive regimens our observation might
raise awareness in cases of unexplained ascites formation
in transplant as well as non-transplant patients.
Patient perspective
“Shortly after the surgery when the ascites occurred I felt
desperate and unsure about ever leaving the hospital
again. It took many weeks until I was finally able to go
home but still needed weekly paracenteses treatments as
outpatient. During this time I decided to insist with my
doctors to resolve this problem because I felt my life had
become unbearable. I started studying the drug informa-
tion sheets of my medication and read about the poten-
tial side effect of ascites. I also had an aunt who was a
kidney transplant recipient and was treated with cyclo-
sporine A and azathioprine for many years and after
switching her to tacrolimus and MPA later in life she felt
increased abdominal fullness and volume. With this
personal experience and reading about the side effects I
suggested to my doctors repeatedly a switch from tacroli-
mus to cyclosporine A. After this change I felt better in
general but the ascites persisted. When the change of
MPA to azathioprine was done I slowly felt a relieve of the
abdominal tension. The re-challenge with MPA made me
then feel “like a balloon” after just a couple of doses.”
“I have never regretted the decision to have a kidney
and pancreas transplantation, despite the complicated
course I would always do it again. The full glycemic con-
trol and cessation of dialysis are important assets in my
life that I would not want to miss any more.”
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